March 2022
Precision Genomics Moves Toward Increased Granularity in Molecular Sequencing
March 10th 2022Kelvin P. Lee, MD, discusses the nuances of an effective molecular tumor board, explains the practical application of precision oncology genomics, and highlights the pathways that have the potential to change the treatment landscape for precision oncology.
Increasing Treatment Pathways Pave the Way for Heartening Future Throughout Hematologic Malignancies
March 9th 2022Stephen Oh, MD, PhD, discusses current and emerging agents in myelofibrosis, advances in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, updates in acute and chronic graft-vs-host-disease, and chronic lymphocytic leukemia management.
Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML
February 28th 2022Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.
